Tex (V.B.S., S.C., P.M.V.), and the Department of Applied Physiology, University of Freiburg (Germany) (B.S.-U., R.B.). Correspondence to V.B. Schini, PhD, Zentrum der Physiologie,
Experiments were designed to examine whether or not insulinlike growth factor I (IGF-I), which is produced by vascular cells in response to injury, affects the production of nitric oxide evoked by the inducible nitric oxide synthase in cultures of smooth muscle cells from the rat aorta. Nitric oxide production was assessed indirectly by the measurement of nitrite accumulation and nitric oxide synthase activity by determining the formation of L-citrulline from L-arginine. Nitric oxide synthase was induced in vascular smooth muscle cells that had been exposed to interleukin-1,8 or tumor necrosis factor-a (TNF-a). IGF-I inhibited, in a concentration-dependent manner, the production of nitrite and L-citrulline evoked by IL- 1, 8 or TNF-a. The inhibition caused by IGF-1 required the presence of the growth factor during the induction of nitric oxide synthase. Two IGF-I-related proteins, IGF-II and insulin, also inhibited, but to a smaller extent, the release of nitrite and the formation of L-citrulline stimulated by IL-1,B. Under bioassay conditions, the perfusates from columns containing IL-1p-treated smooth muscle cells relaxed rings of rat aorta without endothelium that had been contracted with phenylitric oxide is a multifunctional mediator that N contributes to the control of vascular functions in both health and disease.1-3 In healthy blood vessels, nitric oxide is produced mostly by endothelial cells, which possess a constitutively expressed nitric oxide synthase.3 The major functions of nitric oxide in the vascular system include the inhibition of vascular tone and growth and the prevention of platelet activation.3,4 These biologic responses are likely to involve the activation of soluble guanylyl cyclase, which leads to the production of cGMP in the target cells. 5 The injury (eg, after balloon catheterization) to the vascular system often causes the release of inflammatory mediators such as interleukin-l,B (IL-1,B) and tumor necrosis factor-a (TNF-a), which induce a second type of nitric oxide synthase in most types of mammalian cells.4,6 This production of nitric oxide in response to vascular injury may prevent the development of local hyperreactivity and the proliferation of the vascular smooth muscle cells and also contribute to the recovery of the antithrombogenic properties of the injured blood vessel.7-'0 The induction of nitric oxide synthase in vascular smooth muscle cells is controlled by plateletderived peptides such as platelet-derived growth factor and epidermal growth factor and also by blood-derived products such as thrombin and plasmin.10-1 For example, platelet-derived growth factor and thrombin are potent inhibitors of the induction of nitric oxide synthase, whereas epidermal growth factor and plasmin facilitate its expression.
Insulin-like growth factors (IGFs) and insulin are potent mitogens for vascular smooth muscle.14"15 IGF-I circulates at high levels in plasma, and its concentration is dependent on the level of growth hormone.1416 IGF-I and IGF-II are found also in high concentrations in the a-granules of platelets and are released after their aggregation.'718 Cultures of vascular smooth muscle cells secrete IGF-I, and their production is stimulated by platelet-derived growth factor.'9-21 The in vivo injury of blood vessels (eg, aortic coarctation and balloon injury) is associated with the induction of IGF-I mRNA and the presence of intense immunoreactivity for IGF-I in the vascular smooth muscle.22-24 Therefore, it is conceivable that IGF-I and related peptides also modulate the inducible nitric oxide synthase expression in vascular smooth muscle. The present study investigated whether or not IGFs and insulin affect the cytokineinduced production of nitric oxide by the inducible nitric oxide in cultures of smooth muscle cells from the rat aorta.
Materials and Methods Cell Culture
Smooth muscle cells were isolated by elastase and collagenase digestions of thoracic aortas from Wistar rats and characterized by immunocytochemical techniques using specific monoclonal antibodies against smooth muscle a-actin.25 Cells were cultured serially in minimum essential medium (MEM) containing Earle's salts, 2 mmol/L glutamine, 5 mmol/L TES-NaOH (pH 7.3), 5 mmol/L HEPES-NaOH (pH 7.3), 100 U/mL of both penicillin and streptomycin, and 10% (vol/vol) fetal bovine serum. Confluent cultures of smooth muscle cells were passaged by using trypsin-EDTA (1 mmol/L). All experiments were performed with cells between passages 15 and 29 seeded into either 12-well plates for the measurement of nitrite production or in Petri dishes (100 mm in diameter) for the citrulline assay and the expression of inducible nitric oxide synthase mRNA by Northern blot analysis. Bioassay experiments were performed with vascular smooth muscle cells cultured on Cytodex 3 microcarrier beads. When cells reached confluence (0 hour), the culture medium was aspirated and replaced with serum-free culture medium containing 0.1% (wt/vol) fatty acid-free bovine serum albumin to remove factors present in serum. After 24 hours, the culture medium was replaced again with fresh serum-free culture medium containing albumin, and the smooth muscle cells were then exposed to IL-113, TNF-a, or vehicle for 24 hours. In some experiments, when cells reached confluence, the culture medium was replaced with serum-free medium, and IL-1f8 was added directly; in other experiments, the culture medium was replaced with serum-free culture medium when the cells reached confluence and again 24 and 48 hours later before the addition of IL-1,8.
Release of Nitrite
The production of nitrite was determined by diazotization and absorbance reading at 540 nm. 26 Aliquots of conditioned medium from confluent cells (0.4 mL) were collected and mixed with an equal volume of Griess reagent [1% sulfanilamide and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride in 2% phosphoric acid]. The mixture was incubated at room temperature for 10 minutes. Concentrations were determined relative to a standard curve using sodium nitrite. The amount of nitrite present in serum-free culture medium containing albumin was subtracted from that measured in the serum-free culture medium containing albumin that had been exposed to smooth muscle cells.
Citrulline Assay
Confluent smooth muscle cells were washed three times with Tyrode's solution (5 mL) before the addition of 0.5 mL ice-cold homogenization buffer containing 50 mmol/L Tris-HCl (pH 7.4), 1.15% (wt/vol) KCI, 1 mmol/L EDTA, 5 mmol/L glucose, 0.1 mmol/IL DL-dithiothreitol, 200 U/mL superoxide dismutase, 2 mg/L leupeptin, 2 mg/L pepstatin A, 10 mg/L trypsin inhibitor, and 44 mg/L phenylmethylsulfonyl fluoride. The homogenization buffer was aspirated and replaced with fresh homogenization buffer (0.5 mL). The cells were then scraped and collected in Eppendorf tubes. The cells were lysed by five cycles of freezing and thawing (freezing in liquid nitrogen, thawing in a 37°C water bath). Cell cytosols were prepared from lysates by centrifugation at 200% for 10 minutes at 4°C, followed by centrifugation at 10 000g for 15 minutes at 4°C. The cytosols (30 ,uL) were incubated in the presence and absence of nitro-Larginine (1 mmol/L) for 30 minutes at 37°C with 1 gmol/L L-[3H]arginine (1 ,Ci), 1 mmol/L NADPH, 15 gmol/L (6R)-5,6,7,8-tetrahydro-L-biopterin, 1 ,umol/L flavin adeninine dinucleotide, and 1 ,umol/L calmodulin, in 50 mmol/L HEPES buffer (pH 7.4) containing 1 mmol/L DL-dithiothreitol, 1 mmol/L EDTA, and 1.25 mmol/L CaCl2 (final volume, 150 ,uL). The incubations were terminated by the addition of 1 mL ice-cold 100 mmol/L HEPES buffer (pH 5.5) containing 10 mmol/L EGTA and 500 mg AG 5OW-X8 (counterion Nat) cation exchange resin and further incubation for 5 minutes at 4°C, followed by a 5-minute centrifugation at 10 000g. L-[3H]Citrulline in the supernatant was quantified by liquid scintillation counting, and specific nitric oxide synthase activity was calculated as the nitro-L-arginine-sensitive formation of L-[3H]citrulline per minute per milligram of protein. L-Citrulline was quantitatively recovered by this batch assay, as determined by using L-[14C]citrulline. Proteins were measured by using the Bio-Rad protein assay and bovine serum albumin as a standard.
Bioassay Experiments
The thoracic aortas were removed from male Wistar rats anesthetized by an intraperitoneal injection of sodium pentobarbital (50 mg/kg). The blood vessels were placed in a physiological salt solution containing (mmol/L) NaCl, 118.3; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25.0; calcium edetate, 0.026, and glucose 11.1 (control solution).
The arteries were cleaned of fat and connective tissue and cut into rings (3 to 4 mm long). The endothelium was removed mechanically by inserting the tip of a pair of forceps into the lumen and rolling the tissue back and forth, several times, on a paper towel wetted with physiological salt solution. The rings were suspended between two stirrups, one anchored to a steel plate and the other connected to a strain-gauge transducer (model FTO3D, Grass Instrument Co, Quincy, Mass) to record changes in isometric tension. The detector rings were superfused with the perfusate from empty polypropylene columns (direct superfusion) or from columns containing microcarrier beads covered with smooth muscle cells. The columns were perfused at constant flow (3 mL/min) with control solution at 37°C and bubbled with a 95% 02-5% CO2 gas mixture. At the beginning of the experiments, the detector rings were placed under the direct superfusion line and were stretched progressively, by increments of 0.5 g, until the optimal point of their length-active tension curve (2.5 g) was reached. The aortic rings were contracted with phenylephrine (10-6 mol/L). Once the contractions reached a plateau, the preparations were washed with control solution for 45 minutes before being contracted a second time with phenylephrine. The absence of the endothelium was confirmed by the lack of relaxation evoked by acetylcholine (10-6 mol/L). Columns containing cells were perfused for 20 minutes before the beginning of the experiments to wash out the conditioned cultured medium. The detector rings were then moved from the perfusates from the direct line to those from columns containing smooth muscle cells. All experiments were performed in the presence of indomethacin (10`mol/L) to prevent the production of vasoactive prostanoids. At the end of the experiment, the microcarrier beads covered with smooth muscle cells from each column were collected and incubated with trypsin-EDTA. The number of smooth muscle cells per column was determined with the use of a Coulter Counter (Coulter Electronics Limited, Bedfordshire, England).
Platelet Aggregation Experiments
Venous blood was collected from healthy human volunteers, who did not take any medication for at least 1 week, in 10% (vol/vol) of 3.8% sodium citrate. After centrifugation at 200g for 20 minutes at room temperature, 20% (vol/vol) acid citrate-dextrose (mmol/L: trisodium citrate, 85; citric acid, 71; and glucose, 111) and 300 ng/mL prostacyclin were added to the platelet-rich plasma. The platelet-rich plasma was centrifuged at 800g for 10 minutes, and the pellet was resuspended in Tyrode's solution (mmol/L: CaCl2, 1.8; KCl, 2.7; MgCl2, 0.23; NaCl, 137; NaH2PO4, 0.36; glucose, 5.0; and HEPES, 10; pH 7.4) containing 200 ,ug/mL apyrase (grade III), 25 U/mL heparin, and 300 ng/mL prostacyclin. After a further centrifugation at 800g for 10 minutes, the platelets were resuspended in Tyrode's solution and kept for 30 minutes at 37°C. There- Incubation period in serum-free culture medium after, the platelets were stored at room temperature. Platelet aggregation was measured with the nephelometric technique.27 Suspensions of washed platelets (450 ,uL, 2.5 x 108 platelets per milliliter) were incubated at 37°C for 2 minutes in an aggregometer (Elvi 340, Logos GmbH, Hamburg, Germany) with continuous stirring at 1000 rpm and then stimulated with thrombin. Where indicated, microcarrier beads covered with smooth muscle cells were added to the platelet suspension 1 minute before thrombin stimulation. Both platelets and vascular smooth muscle cells were treated with indomethacin (10-5 mol/L) for at least 20 minutes before the assay.
Inducible Nitric Oxide Synthase mRNA Determination
Total cellular RNA was prepared by acid guanidinium thiocyanate extraction as described previously28 and quantitated by absorbance at 260 nm. Total RNA was size-fractionated by electrophoresis on 1% agarose gels containing 2.2 mol/L formaldehyde in a buffer of 20 mmol/L MOPS, 5 mmol/L sodium acetate, and 1 mmol/L EDTA, pH 7.0. RNA was transferred to nylon membranes (Hybond-N, Amersham-Buchler, Braunschweig, Germany) and fixed by baking at 80°C for 2 hours. The membranes were prehybridized at 42°C for 16 hours in a buffer containing 50% formamide, 5x Denhardt's solution, 5x standard saline buffer, 50 mmol/L sodium phosphate buffer, pH 6.6, 0.2% sodium dodecyl sulfate, and 250 ,g/mL denatured salmon sperm DNA. A HincII-Ssp I DNA restriction fragment of the cloned mouse inducible nitric oxide synthase29 was labeled with 30 ,uCi a-[32P]deoxycytidine 5'triphosphate (3000 Ci/mmol, Amersham-Buchler) using a labeling kit from Pharmacia, Freiburg, Germany. The 32p_ labeled DNA was purified by gel filtration (Nick columns, Pharmacia). The Northern blots were hybridized in the same buffer as for prehybridization at 42°C for 16 to 
Statistical Analysis
Results are shown as mean±SEM. Statistical analysis was performed by use of Student's paired (two-tailed) t test and an ANOVA when more than two treatments were compared. A value of P<.05 was considered to be statistically significant.
Results
Treatment of confluent cultures of smooth muscle cells from rat aortas with IL-ll3 in serum-free culture medium caused the accumulation of nitrite into the incubation medium (Fig 1) . The release of nitrite stimulated by IL-1,8 was significantly greater in vascular smooth muscle cells not preexposed to serum-free culture medium compared with nitrite release from cells exposed to serum-free culture medium for 24 or 48 hours before the addition of IL-1/3 (incubation medium was replaced with serum-free culture medium every 24-hour period and before treatment; Fig 1) . In cells not preexposed to serum-free medium, changing the medium once or twice with serum-free medium before exposure to IL-1p3 did not significantly affect the release of nitrite (data not shown). The simultaneous treatment of the smooth muscle cells with IL-1,B (30 U/mL) and IGF-I (30 ng/mL) significantly reduced, by approximately 27%, the release of nitrite caused by IL-1,8 in cells that had not been preexposed to serum-free culture medium before the experiment (Fig 1) . Washing the cells once or twice with serum-free culture medium (0.5 mL) before the addition of IL-1,8 further enhanced the inhibitory effect of the growth factor (data not shown). The growth factor also reduced, by approximately 50%, the release of nitrite caused by IL-lp (30 U/mL) in cells that had been preexposed to serum-free medium for 24 hours before the experiment but did not significantly affect the small release of nitrite evoked by IL-1,3 (30 U/mL) in cells that had been incubated in serum-free medium for 48 hours before the experiment (Fig 1) . The further characterization of the inhibitory effect of IGF-I on the induced nitric oxide formation was performed in cultured vascular smooth muscle cells incubated for 24 hours in serum-free medium. The inhibitory effect was dependent on the concentration of both IGF-I and IL-1X3 (Fig 2) . Similarly, the treatment of vascular smooth muscle cells with TNF-a was also associated with the release of nitrite into the incubation medium, which was inhibited, in a concentration-dependent manner, by IGF-I (Fig 3) . The inhibitory response of IGF-I (30 ng/mL) on the release of nitrite caused by IL-1l3 (30 U/mL for 24 hours) required the presence of the growth factor during the induction of nitric oxide synthase (Fig 4) . The simultaneous exposure of vascular smooth muscle cells to IL-1,3 in the presence of either IGF-II or insulin reduced, in a concentration-dependent manner, the release of nitrite caused by the cytokine alone ( Fig 5) . The cytosolic fractions from homogenates of vascular smooth muscle cells that had been treated with IL-1,3 (30 U/mL) for 24 hours significantly stimulated the conversion of L-arginine to L-citrulline ( Fig 6) . The formation of L-citrulline was decreased significantly by the treatment of the cells with IL-1pf (30 U/mL) in combination with increasing concentrations of IGF-I for 24 hours (Fig 6) . The formation of L-citrulline was also decreased significantly by the treatment of the cells with IL-1,8 (30 U/mL) in the presence of IGF-II (100 ng/mL) but not insulin (100 ng/mL) for 24 hours (Fig 7) . IGF-I (100 ng/mL) inhibited the formation of L-citrulline caused by IL-1,B to a greater extent than did IGF-II (100 ng/mL, Fig 7) .
Under bioassay conditions, the perfusates from columns containing IL-1p (10 U/mL for 24 hours)-activated vascular smooth muscle cells relaxed detector rat aortic rings without endothelium that had been contracted with phenylephrine (Fig 8) . The relaxations were dependent on the number of cells and were inhibited by the infusion of nitro-L-arginine over the cell column (Fig 8) . Perfusates from columns containing cells that had been exposed to IL-1f3 (10 U/mL for 24 hours) in combination with IGF-I (30 ng/mL) also relaxed detector rat aortic rings, but to a significantly smaller extent (Fig 8) . Perfusates from columns containing control cells or cells that had been exposed to IGF-I (30 ng/mL) alone affected only minimally the tone of detector rat aortic rings (data not shown). Addition of thrombin to washed and indomethacintreated human platelets caused a submaximal and irreversible aggregation within 5 minutes (Fig 9) . This aggregation was inhibited by the addition of smooth muscle cells that had been exposed to IL-,13 (10 U/mL for 24 hours) before the assay (Fig 9) . The treatment of platelets with methylene blue (10`mol/L for 20 minutes) before the addition of IL-1j3-activated vascular smooth muscle cells prevented the inhibitory response (data not shown). Addition of untreated smooth muscle cells or cells that had been exposed simultaneously to IL-1/3 (10 U/mL) and IGF-I (30 ng/mL) or to IGF-I (30 ng/mL) alone for 24 hours before the assay only minimally affected platelet aggregation (Fig 9) .
The exposure of vascular smooth muscle cells to IL-1l8 (100 U/mL) for 24 hours caused the expression of inducible nitric oxide synthase mRNA (Fig 10) . The level of inducible nitric oxide synthase mRNA was abolished in cells that had been exposed simultaneously to IL-1,3 in combination with IGF-I (30 ng/mL) for 24 hours (Fig 10) . In control untreated cells and in cells exposed to IGF-I (30 ng/mL for 24 hours) alone, no signal for inducible nitric oxide synthase mRNA could be detected (Fig 10) .
Discussion

Mediators of immune and inflammatory responses such as IL-1,8 and TNF-a stimulate the induction of nitric oxide synthase in vascular smooth muscle cells as well as in most other types of mammalian cells.4730-32
The molecular cloning of the inducible nitric oxide synthase from vascular smooth muscle cells indicated that it is distinct from the constitutive types of the enzyme but is similar to that found in cytokine-activated macrophages.33 Structural analogues of L-arginine such as nitro-L-arginine are selective inhibitors of this enzyme. 34 The induction of nitric oxide synthase in vascular smooth muscle cells causes a time-dependent release of nitrite, a stable oxidation product of nitric oxide, into the incubation medium and an intracellular accumulation of cGMP.7,31 The observation that the release of nitrite caused by IL-1,3 is reduced, in a time-dependent manner, by the prior incubation of the cells in serumfree medium suggests that the induction and/or activity of nitric oxide synthase may be dependent on the cellular growth characteristics of vascular smooth muscle cells. When the confluent cultures of vascular smooth muscle cells that had not been preexposed to serum-free medium were washed with serum-free medium, the release of nitrite caused by IL-1,8 was not affected. Therefore, the presence of remaining serumderived factors in the incubation medium are unlikely to explain the different rates of synthesis of nitric oxide in growing cells (not preexposed to serum-free medium) and in cells that are presumably in a more quiescent state after their exposure to serum-free medium for 48 hours.
The present study demonstrates that IGF-I inhibits the release of nitrite and the formation of L-citrulline from L-arginine in cytokine-activated vascular smooth muscle cells. These inhibitory responses are associated with a decreased release of biologically active nitric oxide, as demonstrated by the relaxation of isolated blood vessels and the inhibition of platelet aggregation. Thus, IGF-I prevents the production of nitric oxide in cytokine-activated vascular smooth muscle cells, possibly by inhibiting the expression of the inducible type of nitric oxide synthase, as suggested by Northern blot analysis. IGF-I decreased the release of nitrite caused by IL-1,8 and TNF-a in vascular smooth muscle cells that had been incubated in serum-free medium for 24 hours before the experiment. The inhibitory effect of IGF-I is concentration dependent and requires the presence of the growth factor during the induction period of nitric oxide synthesis. Cytosolic fractions of homogenates from IL-1p3-activated vascular smooth muscle cells stimulate a nitro-L-arginine-sensitive formation of L-Citrulline from L-arginine. The formation of L-citrulline is reduced significantly when the cells are exposed to IL-1,B in combination with increasing concentrations of IGF-I. All together, these observations support the hypothesis that IGF-I reduces the induction of nitric oxide synthase caused by cytokines in vascular smooth muscle cells. In addition, a decreased affinity and/or number of receptors for IL-1,B and TNF-a may also contribute to explain the inhibitory effect of IGF-I. IGF-I markedly decreased the release of nitrite caused by IL-1,3 in vascular smooth muscle cells that had been incubated for 24 hours in serum-free culture medium and, to a smaller extent, decreased nitrite release in cells that had not been exposed to serum-free medium before their stimulation. Serum contains several proteins that bind IGFs with high affinity (eg, IGF-BP3 and IGF-BP1).14,16
The IGF binding proteins are present in plasma at levels in excess of circulating concentrations of IGFs.1446 Therefore, the small inhibitory effect of IGF-I on the release of nitrite caused by IL-1,8 in cells that had not been exposed to serum-free medium before the assay could be due to the presence of serum-derived binding proteins in the incubation medium. The binding proteins may complex exogenously provided IGF-I and thus decrease the local concentration of IGF-I and, as a consequence, reduce the activation of specific membrane receptors for IGF-I on the vascular smooth muscle cells. This hypothesis is supported Interkeukin-1 n: IL-I n (10 IU/ml) Insulin-like growth factor-l: IGF-I (30 ng/mI) smooth muscle cells (SMCs) from rat aortas that had been exposed to interleukin-1,8 (IL-1 (3, 10 U/mL) for 24 hours on a rat aortc ring without endothelium that had been contracted with phenylephrine (1 0-6 mol/L). The infusion of nitro-L-arginine (3x 10-4 molL) over the cel colmn inhibited the relaxation. The effects of SMCs exposed simuftaneously to insulin-like growth factor (IGF-I, 30 ng/mL) plus IL-1/3 for 24 hours before the experment are shown also. All experiments were performed in the presence of indomethacin (10-5 mol/L). Similar observations were made in seven different experiments.
by the fact that washing the cells (not preexposed to serum-free medium) with serum-free medium before their incubation with IL-1,8 potentiated the inhibitory effect of IGF-I. Alternatively, the presence of serum-derived proteins may affect the number and/or affinity of receptors for IGF-I. IGF-I did not significantly affect the release of nitrite caused by IL-1,8 in vascular smooth muscle cells that had been incubated for 48 hours in serum-free culture medium before their stimulation with the cytokine. Altogether, the present findings would suggest that the inhibitory effect of IGF-I on nitric oxide synthesis in vascular smooth muscle cells is dependent on cellular growth characteristics.
The exposure of vascular smooth muscle cells to IGF-II or insulin in combination with IL-1,B also decreased the release of nitrite and the formation of Tracings showing the effects of smooth muscle cells from rat aortas that had been cultured on microcarrier beads on the aggregation of platelets to thrombin. Suspensions of washed platelets were incubated either alone or with untreated smooth muscle cells (control) or with smooth muscle cells that had been exposed to interleukin-1,8 (IL-1,i, 10 U/mL), insulin-like growth factor (IGF-I, 30 ng/mL), or a combination of IL-1/8 and IGF-1 for 24 hours. The platelet suspensions were incubated with smooth muscle cells (10 pL) for 1 minute before their aggregation by the subsequent addition of thrombin (0.08 U/mL) at arrow. Both platelets and smooth muscle cells were treated with indomethacin ( citrulline caused by the cytokine. However, both IGF-II and insulin were weak inhibitors when compared with IGF-I.
The perfusates from columns containing vascular smooth muscle cells that had been exposed to IL-1,8 before the experiment inhibited the tone of the detector blood vessels without endothelium that had been contracted with phenylephrine.735 The indomethacin-insensitive relaxing activity of the perfusates is dependent on the number of IL-1p-activated vascular smooth muscle cells and is prevented by the infusion of nitro-L-arginine over the cell column or by treatment of the detector blood vessels with methylene blue.735 The addition of IL-1,3-activated vascular smooth muscle cells to indomethacin-treated washed human platelets inhibits their aggregation to thrombin.8"11 The inhibitory response is prevented by the treatment of the platelets with methylene blue and is associated with an enhanced cGMP level in the platelets.8 Untreated vascular smooth muscle cells or cells that had been exposed to IGF-I alone before the experiment minimally affected the tone of detector blood vessels or platelet aggregation. 7, 8, 35 The perfusates from vascular smooth muscle cells that had been exposed simultaneously to IL-1f3 and IGF-I before the experiment also relaxed detector blood vessels but to a smaller extent, and these cells did not affect platelet aggregation. Taken in conjunction, these observations demonstrate that IGF-I impairs the production of biologically active nitric oxide caused by IL-1,8 in vascular smooth muscle cells. Northern blot analysis demonstrated that treatment of vascular smooth muscle cells with IL-113 causes a consistent expression of inducible nitric oxide synthase mRNA. The signal for inducible nitric oxide synthase mRNA was abolished in cultures exposed simultaneously to IL-lf3 in the presence of IGF-I. Thus, IGF-I prevents the induced formation of nitric oxide in cytokine-activated vascular smooth muscle cells by preventing the expression of nitric oxide synthase.
The intravenous administration of IGF-I rapidly (within minutes) produces a sustained increase in renal blood flow and in glomerular filtration rate in both rats and humans. [36] [37] [38] The renal vasodilation induced by IGF-J is abolished completely by an inhibitor of nitric oxide synthase, NG-nitro-L-arginine methyl ester, but only partially by indomethacin in rats.38 These observations suggest that the formation of nitric oxide by a constitutively expressed nitric oxide synthase mediates, at least in part, the enhanced renal blood flow in response to IGF-I. The cellular origin of nitric oxide biosynthesis is unknown. Nitric oxide could possibly originate from endothelial cells, which have a constitutively expressed nitric oxide synthase and specific membrane receptors for IGF-I.1-339 Taken in conjunction with the present findings, those earlier observations imply that IGF-I differentially affects the production of nitric oxide by the constitutive and inducible forms of nitric oxide synthase in vascular cells.
Insulin-like growth factor circulates at high levels in plasma.14 '16 The growth factor is also stored in high concentrations in the a-granules of platelets and is released after their activation.17'18 Cultured endothelial and vascular smooth muscle cells are able to secrete IGF-I.19-21 Platelet-derived growth factor enhances the production of IGF-I in cultured vascular smooth muscle cells.192' The in vivo removal of the intima by the repeated passage of a balloon catheter induces the expression of mRNA for IGF-I and an intense immunoreactivity for IGF-I in the injured vessel wall.22 '24 Balloon injury also causes the production of nitric oxide by the injured blood vessel.6 This endogenous production of nitric oxide, which possibly reflects the induction of nitric oxide synthase in vascular smooth muscle cells after their activation by cytokines, may have a beneficial role rather than cause cytotoxicity. Nitric oxide may protect the vessel wall from spastic responses and prevent an abnormal migration and proliferation of smooth muscle cells.6"10 Nitric oxide is also likely to limit the adhesion and activation of blood cells at sites of injury and thus control the formation of the thrombus and the activation of the coagulation pathway.8 The present findings support the idea that IGF-I may control the induction of nitric oxide synthase at sites of vascular injury. In addition, several other factors that are generated at sites of vascular injury either inhibit (eg, platelet-derived growth factor, TGF-/3, and thrombin)"11"235 or enhance (eg, epidermal growth factor, basic fibroblast growth factor, and plasmin)10"13 the induction of nitric oxide synthase caused by cytokines in cultured vascular smooth muscle cells. Thus, the endogenous production of nitric oxide at sites of vascular injury is likely to be regulated in a coordinated manner by both vascular cell-derived factors and by blood-borne factors. This multifactorial control of the production of nitric oxide may help to determine whether nitric oxide produced in the vascular wall has a beneficial effect (eg, nitric oxide inhibits vascular tone and growth) or detrimental effect (eg, large amounts of nitric oxide are cytotoxic for mammalian cells).
